Institute of Cardiovascular Regeneration

What Institute of Cardiovascular Regeneration does

The Institute of Cardiovascular Regeneration is an academic research institute operating within the Centre for Molecular Medicine at Goethe-University Frankfurt am Main in Germany. The institute conducts basic and translational cardiovascular research across four primary thematic areas: cellular heterogeneity, the vascular niche in aging, long non-coding RNAs and RNA therapeutics, and clonal hematopoiesis. Its core technologies include single-nucleus and single-cell RNA sequencing, spatial transcriptomics, in vivo lineage tracing, AAV9-mediated gene transfer, bone marrow transplantation models, and cardiac MRI analysis. The institute is organized into multiple research groups (Dimmeler Group, Abplanalp Group, Boon Group, Wagner Group) and operates within the Cardio-Pulmonary Institute (CPI) cluster alongside Justus Liebig University Giessen.

The institute's research outputs include peer-reviewed publications in high-impact journals (Nature, Science, Circulation Research, European Heart Journal), novel mechanistic discoveries such as the identification of immunomodulatory endothelial cells and the neurovascular interface aging mechanism, and the first-in-human clinical validation of anti-miR-92a (MRG-110) microRNA therapy. The institute serves academic medical researchers, medical students, and trainees in cardiovascular biology and regenerative medicine.

The institute operates on a non-commercial academic funding model, with revenue derived entirely from competitive research grants and institutional support. Primary funders include the German Research Foundation (DFG), German Center for Cardiovascular Research (DZHK), European Research Council (ERC), and private foundations including Hector Foundations and Dr. Rolf M. Schwiete Foundation. There are no commercial products, software platforms, or fee-for-service offerings; all research output is disseminated through academic channels including publications, conferences, and institutional collaborations.

Name

Institute of Cardiovascular Regeneration

Legal name

Institute of Cardiovascular Regeneration

Website

https://cardiovascular-regeneration.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

The Institute of Cardiovascular Regeneration is an academic research institute at Goethe-University Frankfurt am Main conducting basic and translational cardiovascular research across cellular heterogeneity, vascular aging, RNA therapeutics, and clonal hematopoiesis. It serves academic medical researchers and trainees through grant-funded scientific output.

Ownership category

akta.pro rank

Product category

Academic Cardiovascular Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

akta.pro secondary industries

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL), Neural & Spinal Cord Regeneration (HLAAAGAI), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Cardiovascular regeneration research
• Cardiac aging research
• RNA therapeutics research
• Endothelial cell biology
• Vascular niche research

Headquarters

HQ city

Frankfort

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Grant Funding: Primary funding from German Research Foundation (DFG), German Center for Cardiovascular Research (DZHK), European Research Council (ERC), and various private foundations including Dr. Rolf M. Schwiete Foundation and Hector Foundations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

The Institute of Cardiovascular Regeneration is an academic research institute at Goethe-University Frankfurt am Main that conducts basic and translational cardiovascular research. It investigates cellular heterogeneity, vascular niche in aging, non-coding RNAs and RNA therapeutics, and clonal hematopoiesis through programs organized in research groups (Dimmeler Group, Abplanalp Group, Boon Group, Wagner Group). Outputs include peer-reviewed scientific publications, conference presentations, and supervised training of medical and doctoral students, with no commercial products or services sold.

Product overview

The Institute of Cardiovascular Regeneration is a research institution at Goethe-University Frankfurt am Main, not a commercial product company. The institute conducts fundamental cardiovascular research across multiple thematic areas including cellular heterogeneity, vascular niche in aging, non-coding RNAs and RNA therapeutics, and clonal hematopoiesis. Research outputs consist of scientific publications, collaborative projects, and educational programs rather than commercial products or services. The institute has multiple research groups (Dimmeler Group, Abplanalp Group, Boon Group, Wagner Group) and produces peer-reviewed scientific papers published in journals such as Nature, Science, Circulation Research, and Cardiovascular Research. No commercial products, software platforms, or技术服务 offerings are available for extraction.

Differentiator

Problem solved

Functional benefit

Products and services

• Basic and Translational Cardiovascular Research Program Academic research program producing scientific publications, methodologies, and trained researchers in cardiovascular regeneration and aging; intended for the academic and clinical cardiovascular research community and not sold as a commercial product.

Quantifiable outcome

• First microRNA therapy (anti-miR-92a) demonstrated safe and effective in human subjects for cardiovascular disease
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Cardio-Pulmonary Institute (CPI)coreStrategic or Co-development PartnerMulti-institutional research cluster integrating cardiovascular and pulmonary research across Goethe University Frankfurt and Justus Liebig University Giessen. CPI serves as the umbrella organization for the Institute of Cardiovascular Regeneration and enables interdisciplinary collaboration in cardiopulmonary medicine.
• Justus Liebig University GiessencoreStrategic or Co-development PartnerCollaborating university within Cardio-Pulmonary Institute (CPI) for interdisciplinary cardiopulmonary research. Joint research on neuro-cardiopulmonary interface with Prof. Dr. Dr. Miguel Alejandre Alcazar.
• University Hospital ColognecoreStrategic or Co-development PartnerCollaborating institution for DFG-funded research on neuro-cardiopulmonary interface through Translational Experimental Pediatrics department.
• University of SydneyminorStrategic or Co-development PartnerInternational academic partner hosting Elijah Genetzakis as postdoctoral researcher, with scholarships including James Memorial Scholarship, Royston George Booker Scholarship, and DAAD support for cross-institutional collaboration.
• miRagen Therapeutics / ServierminorStrategic or Co-development PartnerPharmaceutical industry collaborators for microRNA therapy development, specifically anti-miR-92a (MRG-110) clinical trial for cardiovascular disease treatment.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BioCardia: Clinical-stage company developing cell and gene therapies for cardiac conditions, including heart failure. Directly comparable as a cardiac regeneration therapeutic developer with similar target indications (heart failure post-MI).
• Max Planck Institute for Heart and Lung Research: German academic research institute conducting basic and translational research on cardiac and pulmonary biology. Directly comparable to ICR as a peer cardiovascular research institute with similar funding mechanisms (public grants) and publication-led output.
• Tenaya Therapeutics: US-based clinical-stage biotech developing regenerative medicines and gene therapies for heart disease. Operates in the same cardiac regeneration / heart failure space where ICR's basic research creates potential therapeutic targets.
• Viridian Therapeutics (formerly miRagen Therapeutics): Acquired miRagen Therapeutics, which developed MRG-110 (anti-miR-92a) in partnership with ICR for cardiovascular disease. Direct industry partner of ICR's microRNA therapeutic program with shared clinical asset history.
• Capricor Therapeutics: Clinical-stage biotech developing cell and exosome-based therapies for Duchenne muscular dystrophy-associated cardiomyopathy and other cardiac indications. Comparable as a cardiac regeneration therapeutic developer working in adjacent mechanisms to ICR's endothelial cell biology.
• German Heart Institute Berlin (DHZB): Specialized cardiovascular research and treatment center in Germany focused on cardiac surgery, interventional cardiology, and translational research. Comparable as a German cardiovascular research institution with both research and clinical missions.

Regional players

• Karolinska Institutet - Cardiovascular Research Unit: Leading European academic cardiovascular research group based in Sweden. Comparable as a high-impact European cardiovascular research environment with similar publication and grant profile, though geographically distinct.
• Cedars-Sinai Smidt Heart Institute: Major US academic cardiovascular research and clinical center with strong regenerative medicine programs. Comparable as a research-intensive cardiovascular institute with clinical translation capabilities, though geographically distinct.

Broad incumbents

• Novo Nordisk (Cardiovascular & Metabolic): Global pharmaceutical leader with growing cardiovascular and metabolic disease franchises. Comparable as a potential downstream partner/licensor for ICR's cardiovascular targets, particularly in heart failure and metabolic-cardiopulmonary interface.
• Bayer AG (Cardiovascular R&D): Global pharmaceutical company with active cardiovascular R&D and historical presence in German cardiovascular research. Comparable as a large-cap pharma with potential interest in ICR's cardiac regeneration pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/InstCardReg_FFM
• Facebookfacebook.com/profile.php
• Instagraminstagram.com/icr_goethe_uni_frankfurt?igshid=YmMyMTA2M2Y=
• LinkedInlinkedin.com/company/institute-of-cardiovascular-regeneration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute of Cardiovascular Regeneration